Curated News
By: NewsRamp Editorial Staff
May 14, 2025
Silo Pharma Collaborates with Frontage Laboratories to Conduct Safety Study of PTSD Treatment SPC-15
TLDR
- Silo Pharma's partnership with Frontage Labs for a safety study on SPC-15 strengthens its FDA submission, giving a competitive advantage.
- Silo Pharma collaborates with Frontage Labs to conduct a 7-day safety and toxicology study on SPC-15, an intranasal treatment for PTSD.
- Silo Pharma's development of SPC-15, targeting PTSD and stress-related disorders, aims to improve mental health treatments, making tomorrow better than today.
- SPC-15, a 5-HT4 receptor agonist developed by Silo Pharma with Columbia University, offers innovative potential for treating psychiatric disorders like PTSD.
Impact - Why it Matters
This news matters as Silo Pharma's partnership for a safety study of SPC-15 showcases progress in developing treatments for psychiatric disorders. The study's outcomes could potentially expedite the FDA approval process for a novel therapy targeting PTSD, offering hope for patients suffering from stress-related conditions.
Summary
Silo Pharma (NASDAQ: SILO) partners with Frontage Laboratories to conduct a 7-day safety and toxicology study of its lead asset, SPC-15, targeting PTSD and stress-related disorders. The study aims to strengthen Silo's upcoming FDA submission, expected this year, and is running concurrently with a GLP-compliant toxicology study. SPC-15, a 5-HT4 receptor agonist developed with Columbia University, could be eligible for the FDA's 505(b)(2) pathway.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Silo Pharma Collaborates with Frontage Laboratories to Conduct Safety Study of PTSD Treatment SPC-15
